• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Helius Medical Technologies, Inc. Appoints Frederick Fantazzia as Vice President of Sales & Marketing, North America

    6/2/21 7:05:00 AM ET
    $LIVN
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $LIVN alert in real time by email

    NEWTOWN, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced the appointment of Frederick Fantazzia to the position of Vice President of Sales & Marketing, North America, effective June 1, 2021.

    "Fred is a dynamic leader with 16 years of sales and marketing experience in the field of neuromodulation, and a specific focus on developing the market for new neuromodulation technologies by building and leading high-quality sales team to raise awareness and facilitate commercial adoption," said Dane Andreeff, Interim President and Chief Executive Officer of Helius. "We are pleased to welcome him to our leadership team and look forward to his contributions as we continue our pre-commercialization initiatives and prepare to commercialize our PoNS Treatment in the United States."

    "I believe Helius is a rising star in the development of innovative neuromodulation technologies to treat conditions related to the effects of neurological disease and trauma," said Mr. Fantazzia. "With the Company's PoNS device now authorized for sale in the U.S., I am excited to join the team at this important inflection point. I look forward to developing the market for PoNS Treatment and bringing it to U.S. patients suffering from the effects of multiple sclerosis."

    Prior to joining Helius, Mr. Fantazzia worked for LivaNova, PLC (NASDAQ:LIVN), a global medical technology company that designs, develops, manufactures and sells innovative therapeutic solutions in the fields of neuromodulation and cardiovascular disease, from 2016 until 2021. He most recently served as Vice President of North America Sales and Marketing for LivaNova's Epilepsy business, where he managed all aspects related to its commercialization of a neuromodulation technology for the treatment of drug-resistant epilepsy. During his time with LivaNova/Cyberonics Inc., Mr. Fantazzia also served as Vice President of Global Sales and Marketing for its Neuromodulation segment from 2015 to 2016 and Vice President of U.S. Sales from 2016 to 2018.

    Prior to the merger between Sorin S.p.A. and Cyberonics Inc., which combined to form LivaNova in 2015, Mr. Fantazzia worked for Cyberonics Inc. (NASDAQ:CYBX) a medical device company with core expertise in neuromodulation. He joined the company as a Regional Sales Manager in 2005, and subsequently held a series of positions of increasing responsibility, culminating in his promotion to Vice President of Global Sales and Marketing for Neuromodulation in 2015.

    Mr. Fantazzia holds a B.S. in Business Administration from Villanova University.

    About Helius Medical Technologies, Inc.

    Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company's purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain's ability to heal itself. The Company's first commercial product is the Portable Neuromodulation Stimulator (PoNS™). For more information, visit www.heliusmedical.com.

    About the PoNS™ Device and PoNS Treatment™

    The Portable Neuromodulation Stimulator (PoNS™) is an innovative non-surgical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to provide treatment of gait deficit. The PoNS device is indicated for use in the United States as a short term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis ("MS") and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. It is authorized for sale in Canada as a class II, non-implantable, medical device intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS, and chronic balance deficit due to mild-to-moderate traumatic brain injury ("mmTBI") and is to be used in conjunction with physical therapy. The PoNS™ is an investigational medical device in the European Union ("EU") and Australia ("AUS"). It is currently under premarket review by the AUS Therapeutic Goods Administration.

    Investor Relations Contact:

    Westwicke on behalf of Helius Medical Technologies, Inc.

    Jack Powell, Vice President

    [email protected]

    Cautionary Disclaimer Statement: 

    Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as "believe," "continue," "look forward," "will," "committed to," "goal," "expect," "remain," "hope" and similar expressions. Such forward-looking statements include, among others, statements regarding the Company's future growth and operational progress, the next phase of the Company's market development activities, clinical and regulatory development plans for the PoNS device, the timing and success of the Company's commercialization efforts in the United States, and the ability for the Company to develop the market for PoNS Treatment and bringing it to U.S. patients suffering from the effects of multiple sclerosis.

    These statements involve substantial known and unknown risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company's expectations include , uncertainties regarding the Company's capital requirements to achieve its business objectives, the impact of the COVID-19 pandemic, the Company's ability to train physical therapists in the supervision of the use of the PoNS Treatment, the Company's ability to secure contracts with rehabilitation clinics, the Company's ability to obtain national Medicare coverage and to obtain a reimbursement code so that the PoNS device is covered by Medicare and Medicaid, the Company's ability to build internal commercial infrastructure, market awareness of the PoNS device, future clinical trials and the clinical development process, manufacturing and supply chain risks, potential changes to the MCIT program, the product development process and FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and other risks detailed from time to time in the filings made by the Company with securities regulators, including the risks and uncertainties described in the "Risk Factors" sections of the Company's Annual Report on Form 10-K for the year ended December 31, 2020 and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com. The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.

    The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.





    Primary Logo

    Get the next $LIVN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LIVN
    $HSDT

    CompanyDatePrice TargetRatingAnalyst
    LivaNova PLC
    $LIVN
    5/20/2025$60.00Peer Perform → Outperform
    Wolfe Research
    LivaNova PLC
    $LIVN
    2/26/2025Outperform → Peer Perform
    Wolfe Research
    LivaNova PLC
    $LIVN
    10/4/2024$65.00Buy
    Goldman
    LivaNova PLC
    $LIVN
    9/17/2024$55.00 → $66.00Neutral → Outperform
    Robert W. Baird
    LivaNova PLC
    $LIVN
    3/20/2024Buy
    Needham
    LivaNova PLC
    $LIVN
    2/20/2024$60.00 → $70.00Neutral → Buy
    Mizuho
    LivaNova PLC
    $LIVN
    9/6/2023$52.00Hold
    HSBC Securities
    LivaNova PLC
    $LIVN
    7/19/2023$56.00Neutral
    Robert W. Baird
    More analyst ratings

    $LIVN
    $HSDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • LivaNova upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded LivaNova from Peer Perform to Outperform and set a new price target of $60.00

      5/20/25 8:01:26 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova downgraded by Wolfe Research

      Wolfe Research downgraded LivaNova from Outperform to Peer Perform

      2/26/25 7:12:54 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Goldman initiated coverage on LivaNova with a new price target

      Goldman initiated coverage of LivaNova with a rating of Buy and set a new price target of $65.00

      10/4/24 7:42:40 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    $HSDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Andreeff Dane bought $8,229 worth of shares (1,284 units at $6.41) (SEC Form 4) (Amendment)

      4/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      2/15/24 4:06:00 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Andreeff Dane bought $40,475 worth of shares (5,000 units at $8.10) (SEC Form 4)

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      12/15/23 7:00:42 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Andreeff Dane bought $25,675 worth of shares (4,006 units at $6.41) (SEC Form 4)

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      12/4/23 8:30:12 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    $HSDT
    Financials

    Live finance-specific insights

    See more
    • LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

      Delivered high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion Raised full-year 2025 revenue guidance; updated full-year 2025 guidance now incorporates impact of SNIA decision and currently applicable tariffs Completed premarket approval submission for the aura6000™ System intended to treat obstructive sleep apnea Announced 12-month, top-line OSPREY data demonstrating strong response and sustained therapeutic impact for patients who received proximal hypoglossal nerve stimulation for obstructive sleep apnea LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the first quarter

      5/7/25 6:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova to Announce First-Quarter 2025 Results

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2025 results on Wednesday, May 7, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its first-quarter 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 047836. A replay will be available on the LivaN

      3/26/25 8:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2024 results and issued full-year 2025 guidance. Financial Summary and Highlights(1) Fourth-quarter revenue of $321.8 million increased 3.8% on a reported basis, 4.7% on a constant-currency basis, and 6.8% on an organic basis as compared to the prior-year period Fourth-quarter U.S. GAAP diluted earnings per share of $1.02 and adjusted diluted earnings per share of $0.81 Full-year 2024 revenue of $1.25 billion increased 8.7% on a reported basis, 9.3% on a constant-currency basis, and 10.7% on an organic basis as compared to the prior-year Full-year 2024 U.S. GAAP

      2/25/25 6:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    $HSDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CFO and Treasurer Mathiesen Jeffrey S

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      7/3/25 8:00:26 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Favit-Van Pelt Antonella R.

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      7/3/25 8:00:28 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Walter Blane

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      7/3/25 8:00:24 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    $HSDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Helius Medical Technologies Inc.

      SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

      11/8/24 5:12:24 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Helius Medical Technologies Inc.

      SC 13G - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

      5/14/24 4:15:39 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by LivaNova PLC

      SC 13G - LivaNova PLC (0001639691) (Subject)

      4/17/24 4:19:05 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    $HSDT
    SEC Filings

    See more
    • Helius Medical Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

      7/7/25 5:02:35 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 424B5 filed by Helius Medical Technologies Inc.

      424B5 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

      7/7/25 5:00:56 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

      6/27/25 9:00:17 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    $HSDT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Helius Medical Technologies Announces Reverse Stock Split

      NEWTOWN, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-50 reverse split of its Class A common stock, par value $0.001 ("common stock"), effective at 5:00 pm Eastern time on June 30, 2025. Beginning on July 1, 2025, the Company's common stock will trade on The Nasdaq Capital Market on a split adjusted basis. At the Company's special meeting of stockholders on May 23, 2025, the stockholders approved a proposal to amend the Company's Certificate of Incorporation to effect a reverse s

      6/27/25 8:30:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device

      - CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161- -This follows another recent authorization by Anthem Multiplan for PoNS Device at out-of-network negotiated price of $19,160- NEWTOWN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an additional authorized claim for payment for the PoNS Device from CignaHealth. CignaHealth becomes the fifth major payer to authorize claims for payment for the PoNS Device

      6/16/25 7:00:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting

      -PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of full PoNSTEP study results expanded upon top line data previously reported- NEWTOWN, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Deborah Backus, PT, Ph.D., FACRM- Vice President of Research and Innovation at Atlanta's Shepard Center presented the positive results from the PoNS Therapeutic Experience Program, or

      6/12/25 6:59:59 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    $HSDT
    Leadership Updates

    Live Leadership Updates

    See more
    • Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device

      -Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS- NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an authorized claim for payment for the PoNS Device from a third major healthcare provider, Aetna Healthcare. "The recent reimbursement approvals from two major

      6/11/25 7:00:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting

      NEWTOWN, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced it will highlight the results of a new study confirming the therapeutic regimen and sustained efficacy of its Portable Neuromodulation Stimulator (PoNS®) device for people with multiple sclerosis (MS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. The event runs from May 28-31 at the Phoenix Convention Center in Phoenix. Deborah Backus, PT, Ph.D., FACRM – Vice President of Research and Innovation at Atlanta's Shepherd Center, one of six sit

      5/20/25 7:00:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

      1/6/25 9:00:00 AM ET
      $ABT
      $BMY
      $IRM
      $LIVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Real Estate Investment Trusts
      Real Estate